Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Dec;27(12):2734-42.
doi: 10.1007/s11095-010-0274-8. Epub 2010 Sep 25.

Topical delivery of a naproxen-dithranol co-drug: in vitro skin penetration, permeation, and staining

Affiliations

Topical delivery of a naproxen-dithranol co-drug: in vitro skin penetration, permeation, and staining

Wing Man Lau et al. Pharm Res. 2010 Dec.

Abstract

Purpose: This work probed the topical delivery and skin-staining properties of a novel co-drug, naproxyl-dithranol (Nap-DTH), which comprises anti-inflammatory (naproxen) and anti-proliferative (dithranol) moieties.

Method: Freshly excised, full-thickness porcine ear skin was dosed with saturated solutions of the compounds. After 24 h, the skin was recovered and used to prepare comparative depth profiles by the tape-stripping technique and to examine the extent of skin staining.

Results: Depth profiles showed that Nap-DTH led to a 5-fold increase in drug retention in the skin compared to dithranol. The application of Nap-DTH also demonstrated improved stability, resulting in lower levels of dithranol degradation products in the skin. Furthermore, significantly less naproxen from hydrolysed Nap-DTH permeated into the receptor phase compared to naproxen when applied alone (0.08 ± 0.03 nmol cm(-)² and 180 ± 60 nmol cm(-)², respectively). Moreover, the reduced staining of the skin was very apparent for Nap-DTH compared to dithranol.

Conclusions: Topical delivery of Nap-DTH not only improves the delivery of naproxen and dithranol, but also reduces unwanted effects of the parent moieties, in particular the skin staining, which is a major issue concerning the use of dithranol.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Drug Discov Today. 2001 Oct 1;6(19):985-986 - PubMed
    1. J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S67-80 - PubMed
    1. Ann Anat. 2007;189(2):143-56 - PubMed
    1. J Pharm Pharmacol. 2007 Jul;59(7):917-25 - PubMed
    1. Int J Pharm. 2001 Apr 17;217(1-2):127-37 - PubMed

Publication types

MeSH terms

LinkOut - more resources